All In Biotech

Drug Trial Radar · NCT07903272

A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible

A Phase 3 Randomized Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) and Daratumumab and Lenalidomide (DR) Maintenance (DVRd + High-dose Therapy [HDT] + ASCT + DR) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Dec 14, 2026

Primary completion

Jan 11, 2037

Study completion Jan 11, 2037

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
European Myeloma Network B.V.
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare how well Ramantamig plus Daratumumab (ramantamig-D) works compared with a treatment that includes Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd), followed by high-dose therapy, autologous stem cell transplantation (using the participant's own stem cells), and maintenance treatment with Daratumumab and Lenalidomide (DR) in participants with newly diagnosed multiple myeloma (NDMM), a blood cancer affecting plasma cells, who are eligible for transplant.

Conditions

  • Multiple Myeloma

Interventions

  • RamantamigDrug

    Ramantamig will be administered as subcutaneous (SC) injection.

  • DaratumumabDrug

    Daratumumab will be administered as SC injection.

  • BortezomibDrug

    Bortezomib will be administered as SC injection.

  • LenalidomideDrug

    Lenalidomide will be administered orally.

  • DexamethasoneDrug

    Dexamethasone will be administered orally or intravenously (IV).

  • HDT+ASCTDrug

    HDT and ASCT will be performed as per standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to approximately 10 years
  2. Percentage of Participants Achieving 12-Month Minimal Residual Disease (MRD)-Negative Complete Response (CR)Time frame: Up to approximately 12 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.